This site is intended for Great Britain healthcare professionals only 
Sign in
Sign in
Sign out

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Explore Content

Information on how to access Cibinqo®▼ (abrocitinib) prescribing information and adverse event reporting can be found at the bottom of the page.

PATIENT PROFILE 1

Unemployed male with increasingly uncontrolled itching leading to sleep deprivation, weight gain and low self-esteem​​​​​​​​​​​​​​


​​​​​​​Who is the patient?

    This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.​​​​​​​
    • ​​​​​​​Caucasian male, 28 years old

    • Disease and treatment history: Worsening AD for 5–6 years, despite topical corticosteroids, TCI and phototherapy; occasional, mild keratitis, despite no longer wearing contact lenses.
    • Clinical assessment: EASI=26; 45% BSA (including the head and neck); persistent itching resulting in sleep deprivation; BMI 32
    • Personal impact: Daily life adversely affected: reluctant to leave the house, weight gain due to poor diet and little exercise, low self-esteem, ability to find employment negatively impacted.

    ​​​​​​​

    Why consider Cibinqo (abrocitinib)?

    1. Cibinqo used in combination with topical therapy provides skin clearance at Week 12 in significantly more patients compared with placebo1,2

    JADE COMPARE (CO-PRIMARY ENDPOINTS, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)

    Proportion of patients achieving IGA 0/1

    IGA 0/1 at Week 12

    no./Total no. (%, 95% CI)

    Cibinqo 200 mg

    106/219 (48.8%; 41.8–55.0

    Cibinqo 100 mg

    86/235 (36.6%; 30.4–42.8)

    Dupilumab 300 mg

    88/241 (36.5%; 30.4–42.6)

    Placebo

    18/129 (14.0%; 8.0–19.9)

    Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

    Proportion of patients achieving EASI-75

    EASI-75 at Week 12

    no./Total no. (%, 95% CI)

    Cibinqo 200 mg

    154/219 (70.3%; 64.3–76.4)

    Cibinqo 100 mg

    138/235 (58.7%; 52.4–65.0)

    Dupilumab 300 mg

    140/241 (58.1%; 51.9–64.3)

    Placebo

    35/129 (27.1%; 19.5–34.8)

    Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

    2. Cibinqo 200 mg provides superior itch response vs dupilumab at Week 21–3

    JADE COMPARE (KEY SECONDARY ENDPOINT, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)

    Proportion of patients achieving PP-NRS4

    PP-NRS4 is defined as an improvement of ≥4 points from baseline in the severity of PP-NRS. Cibinqo 200 mg was compared with dupilumab in the key secondary head-to-head endpoint, PP-NRS4 at Week 2. This endpoint was further analysed as prespecified multiplicity-controlled analysis and showed superiority to dupilumab down to Day 4. 

    3. Cibinqo reduces AD-related sleep loss1,3

    JADE COMPARE (SECONDARY ENDPOINT, IN COMBINATION WITH MEDICATED TOPICAL THERAPY)

    % reduction (improvement) in SCORAD sleep loss subscale at Week 12

    Change from baseline in SCORAD sleep loss is a prespecified secondary endpoint not controlled for multiplicity, therefore treatment differences could represent chance findings. 

    ​​​​​​​Analyses shown are between Cibinqo and placebo. Results are not to be interpreted as evidence of superiority, noninferiority, or similarity between Cibinqo and dupilumab.

    Explore more

    Patient 2

    Middle-aged mother with uncontrolled, severe eczematous lesions, resulting in selfconsciousness and anxiety.

    View profile

    Patient 3

    Young professional female with persistent, uncontrolled itching and lesions that are impacting her work.

    View profile

    This patient profile is fictional and has been produced for the purposes of medical education. Any actual or potential likeness to real individuals is unintentional.​​​​​​​

    AD=atopic dermatitis; BMI=body mass index; BSA=body surface area; CI​​​​​​​=confidence interval; EASI=Eczema Area and Severity Index; IGA=Investigator’s Global Assessment; LSM=least squares mean; PP-NRS=Peak Pruritus Numerical Rating Scale; SCORAD=SCORing Atopic Dermatitis; TCI=topical calcineurin inhibitor.
    References: 1. Cibinqo (abrocitinib) Summary of Product Characteristics. 2. Bieber T, et al. N Engl J Med 2021;384(12):1101–1112. 3. Bieber T, et al. N Engl J Med 2021;384(12):1101–1112. Supplementary appendix.
    PP-CIB-GBR-0056. October 2021

    Cibinqo Risk Minimisation Programme (RMP) materials, including a Patient Card and Prescriber Brochure, are available from https://www.medicines.org.uk/emc. Patients treated with Cibinqo should be given the Patient Card.

    For UK Healthcare Professionals*

    These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

    I confirm that I am a healthcare professional* resident in the United Kingdom.

    If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

    *The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

    PP-PFE-GBR-3863. November 2021

    Yes

    No